Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7669599 | 0.99 | POLB (0.68) | POLBHPGDKMT2AKDM4ENPC1 | |
| SCHEMBL6219851 | 0.91 | POLB (0.67) | POLBHPGDKMT2AKDM4ENPC1 | |
| Hydrochloric Acid SCHEMBL7667624 | 0.90 | POLB (0.66) | POLBHPGDKMT2AKDM4ENPC1 | |
| SCHEMBL6220875 | 0.88 | POLB (0.62) | POLBHPGDKMT2AKDM4ENPC1 | |
| Hydrochloric Acid SCHEMBL7885965 | 0.87 | POLB (0.61) | POLBHPGDKMT2AKDM4ENPC1 | |
| SCHEMBL7673406 | 0.86 | POLB (0.73) | POLBHPGDKMT2AKDM4ENPC1 | |
| SCHEMBL7960442 | 0.84 | POLB (0.80) | POLBHPGDKMT2AKDM4ENPC1 | |
| SCHEMBL7959850 | 0.83 | POLB (0.85) | POLBHPGDKMT2AKDM4ENPC1 | |
| SCHEMBL6221582 | 0.83 | HPGD (0.68) | POLBHPGDKMT2AKDM4ENPC1 | |
| SCHEMBL7960878 | 0.83 | KDM4E (0.87) | POLBHPGDKMT2AKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1107966-B1 | OXO-PYRIDOIMIDAZOLE-CARBOXAMIDES: GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2005-07-27 | — | — | EP | claimed |
| US-6451809-B2 | COGNITION ACTIVATORS; PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2002-09-17 | — | — | US | claimed |
| US-20010011133-A1 | Oxo-pyridoimidazole-carboxamides: GABA brain receptor ligands | NEUROGEN CORPORATION. | 2001-08-02 | — | — | US | claimed |
| US-6177569-B1 | DIAGNOSIS AND TREATMENT OF ANXIETY, DOWN SYNDROME, DEPRESSION, SLEEP, COGNITIVE AND SEIZURE DISORDERS, OVERDOSE WITH BENZODIAZEPINE DRUGS AND FOR ENHANCEMENT OF ALERTNESS | NEUROGEN CORPORATION | 2001-01-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011133-A1 | Oxo-pyridoimidazole-carboxamides: GABA brain receptor ligands | GABRA1, GABRA4, GABRB1 | POLB 2024/4885HPGD 3204/4885KMT2A 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.